Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions
Table 1
Phase III randomized controlled trials of tocilizumab for RA patients. Summary of the results of seven phase III randomized controlled trials of tocilizumab. DMARDs: disease modifying antirheumatic drugs, IR: inadequate response, TCZ: tocilizumab, anti-TNF: anti-tumor necrosis factor inhibitor, MTX: methotrexate.